Cargando…
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II
Background: Krebs von den Lungen-6 (KL-6) has been proposed as a disease severity marker of COVID-19. All research articles reported the KL-6 assay detected through Fujirebio reagents by Lumipulse G600/G1200 instrument. In the present study, KL-6 assay was analysed through Tosoh AIA-360 and compared...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8872393/ https://www.ncbi.nlm.nih.gov/pubmed/35206372 http://dx.doi.org/10.3390/ijerph19042176 |
_version_ | 1784657228377096192 |
---|---|
author | d’Alessandro, Miriana Bergantini, Laura Cavallaro, Dalila Gangi, Sara Cameli, Paolo Conticini, Edoardo Frediani, Bruno Dotta, Francesco Bargagli, Elena |
author_facet | d’Alessandro, Miriana Bergantini, Laura Cavallaro, Dalila Gangi, Sara Cameli, Paolo Conticini, Edoardo Frediani, Bruno Dotta, Francesco Bargagli, Elena |
author_sort | d’Alessandro, Miriana |
collection | PubMed |
description | Background: Krebs von den Lungen-6 (KL-6) has been proposed as a disease severity marker of COVID-19. All research articles reported the KL-6 assay detected through Fujirebio reagents by Lumipulse G600/G1200 instrument. In the present study, KL-6 assay was analysed through Tosoh AIA-360 and compared with analytical results by Lumipulse G600 in a population of COVID-19 patients. Materials and methods: Sixty-four patients (median age, IQR 67 (58–76) years), all hospitalized for COVID-19 interstitial pneumonia at Siena COVID Unit. KL-6 was measured by two methods, chemiluminescence enzyme immunoassay (CLEIA) and fluorescent enzyme immunoassay (FEIA) method by Lumipulse G600 II and AIA 360 systems, respectively. Results: KL-6 concentrations evaluated by Lumipulse G600II were significantly higher in severe than those in non-severe patients (p < 0.0001) as well as evaluating by AIA360 (p < 0.0001). Receiver operating curve (ROC) curve analysis showed that KL-6 concentrations, by Lumipuse G600II, distinguished severe from non-severe COVID-19 patients with an area under the curve (AUC) of 99.8% and the best cut-off value was 448 U/mL. AUROC between severe and non-severe COVID-19 patients using T0 KL-6 concentrations by AIA360 was 97.4% and the best cut-off value was 398 U/mL. According to T0 KL-6 concentrations in COVID-19 patients, Bland–Altman difference analysis revealed a mean bias of 78 ± 174.8; while using T1 KL-6 concentrations in COVID-19 patients, Bland–Altman difference analysis revealed a mean bias of 48 ± 126 (95% limits of agreement −199–295) between the Lumipulse G600 II and the AIA360 systems. Conclusions: In conclusion, our study demonstrated that CLEIA and FEIA methods for serum KL-6 detection are comparable and reliable. KL-6 was confirmed as an easily detectable and effective biomarker to identify severe COVID-19 patients. |
format | Online Article Text |
id | pubmed-8872393 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88723932022-02-25 Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II d’Alessandro, Miriana Bergantini, Laura Cavallaro, Dalila Gangi, Sara Cameli, Paolo Conticini, Edoardo Frediani, Bruno Dotta, Francesco Bargagli, Elena Int J Environ Res Public Health Article Background: Krebs von den Lungen-6 (KL-6) has been proposed as a disease severity marker of COVID-19. All research articles reported the KL-6 assay detected through Fujirebio reagents by Lumipulse G600/G1200 instrument. In the present study, KL-6 assay was analysed through Tosoh AIA-360 and compared with analytical results by Lumipulse G600 in a population of COVID-19 patients. Materials and methods: Sixty-four patients (median age, IQR 67 (58–76) years), all hospitalized for COVID-19 interstitial pneumonia at Siena COVID Unit. KL-6 was measured by two methods, chemiluminescence enzyme immunoassay (CLEIA) and fluorescent enzyme immunoassay (FEIA) method by Lumipulse G600 II and AIA 360 systems, respectively. Results: KL-6 concentrations evaluated by Lumipulse G600II were significantly higher in severe than those in non-severe patients (p < 0.0001) as well as evaluating by AIA360 (p < 0.0001). Receiver operating curve (ROC) curve analysis showed that KL-6 concentrations, by Lumipuse G600II, distinguished severe from non-severe COVID-19 patients with an area under the curve (AUC) of 99.8% and the best cut-off value was 448 U/mL. AUROC between severe and non-severe COVID-19 patients using T0 KL-6 concentrations by AIA360 was 97.4% and the best cut-off value was 398 U/mL. According to T0 KL-6 concentrations in COVID-19 patients, Bland–Altman difference analysis revealed a mean bias of 78 ± 174.8; while using T1 KL-6 concentrations in COVID-19 patients, Bland–Altman difference analysis revealed a mean bias of 48 ± 126 (95% limits of agreement −199–295) between the Lumipulse G600 II and the AIA360 systems. Conclusions: In conclusion, our study demonstrated that CLEIA and FEIA methods for serum KL-6 detection are comparable and reliable. KL-6 was confirmed as an easily detectable and effective biomarker to identify severe COVID-19 patients. MDPI 2022-02-15 /pmc/articles/PMC8872393/ /pubmed/35206372 http://dx.doi.org/10.3390/ijerph19042176 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article d’Alessandro, Miriana Bergantini, Laura Cavallaro, Dalila Gangi, Sara Cameli, Paolo Conticini, Edoardo Frediani, Bruno Dotta, Francesco Bargagli, Elena Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II |
title | Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II |
title_full | Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II |
title_fullStr | Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II |
title_full_unstemmed | Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II |
title_short | Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II |
title_sort | krebs von den lungen-6 as disease severity marker for covid-19 patients: analytical verification and quality assessment of the tosoh aia-360 compared to lumipulse g600ii |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8872393/ https://www.ncbi.nlm.nih.gov/pubmed/35206372 http://dx.doi.org/10.3390/ijerph19042176 |
work_keys_str_mv | AT dalessandromiriana krebsvondenlungen6asdiseaseseveritymarkerforcovid19patientsanalyticalverificationandqualityassessmentofthetosohaia360comparedtolumipulseg600ii AT bergantinilaura krebsvondenlungen6asdiseaseseveritymarkerforcovid19patientsanalyticalverificationandqualityassessmentofthetosohaia360comparedtolumipulseg600ii AT cavallarodalila krebsvondenlungen6asdiseaseseveritymarkerforcovid19patientsanalyticalverificationandqualityassessmentofthetosohaia360comparedtolumipulseg600ii AT gangisara krebsvondenlungen6asdiseaseseveritymarkerforcovid19patientsanalyticalverificationandqualityassessmentofthetosohaia360comparedtolumipulseg600ii AT camelipaolo krebsvondenlungen6asdiseaseseveritymarkerforcovid19patientsanalyticalverificationandqualityassessmentofthetosohaia360comparedtolumipulseg600ii AT conticiniedoardo krebsvondenlungen6asdiseaseseveritymarkerforcovid19patientsanalyticalverificationandqualityassessmentofthetosohaia360comparedtolumipulseg600ii AT krebsvondenlungen6asdiseaseseveritymarkerforcovid19patientsanalyticalverificationandqualityassessmentofthetosohaia360comparedtolumipulseg600ii AT fredianibruno krebsvondenlungen6asdiseaseseveritymarkerforcovid19patientsanalyticalverificationandqualityassessmentofthetosohaia360comparedtolumipulseg600ii AT dottafrancesco krebsvondenlungen6asdiseaseseveritymarkerforcovid19patientsanalyticalverificationandqualityassessmentofthetosohaia360comparedtolumipulseg600ii AT bargaglielena krebsvondenlungen6asdiseaseseveritymarkerforcovid19patientsanalyticalverificationandqualityassessmentofthetosohaia360comparedtolumipulseg600ii |